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Background: The histopathologic distinction between typical carcinoid (TC) and atypical carcinoid (AC) of the lung
is based largely on mitotic index. Ki-67 may aid in separation of these tumors, as well as the distinction from large
cell neuroendocrine carcinoma (LCNEC).
Methods: We identified 55 surgically resected primary neuroendocrine lung tumors (39 TC, 7 AC, 9 LCNEC) based
on mitotic rate and histologic features. Ki-67 proliferative index based on automated image analysis, tumor necrosis,
nodal metastases, local or distant recurrence, and survival were compared across groups.
Results: The mean mitotic count and Ki-67 index for TC, AC, and LCNEC were 0.1 and 2.3%, 3.4 and 16.8%, and 56.1
and 81.3% respectively. The Ki-67 index did not overlap among groups, with ranges of 0–6.7% for TC, 9.9-25.7% for
AC, and 63.2-91.9% for LCNEC. Nodal metastases were identified in 4/39 (10%) TC, 2/7 (22%) AC, and 2/8 (25%)
LCNEC. There was no survival difference between TC and AC, but there was a significant survival difference between
LCNEC and TC and AC combined (p < 0.001). There was a step-wise increase in disease free survival with tumor
grade: no TC recurred, 2/7 AC recurred or progressed (median interval 35.5 months), and all LCNEC recurred or
progressed (median interval 10.1 months). No patient with TC or AC died of disease, compared to 7/8 LCNEC with
follow-up data.
Conclusions: We conclude that Ki-67 index is a useful diagnostic marker for neuroendocrine tumors, with 7% a
divider between AC and TC, and 50% a divider between LCNEC and AC. LCNEC is biologically different from AC
and TC, with a much more aggressive course, and a high Ki-67 index.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_174
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Neuroendocrine tumors of the lung account for approxi-
mately 20-25% of primary lung tumors [1]. The most
common type is small cell carcinoma, accounting for
15-20%, followed by large cell neuroendocrine carcinoma
(LCNEC) (~3%), typical carcinoid (TC), and atypical car-
cinoid (AC) tumors (~1-2%). Other than small cell carcin-
omas, neuroendocrine tumors are typically initially treated
by surgical excision. The distinction between these four
tumor types is based on histologic features, mitotic index,* Correspondence: Allen.burke@gmail.com
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unless otherwise stated.and presence or absence of necrosis [1,2]. Of these fea-
tures, mitotic figures are particularly important in separat-
ing AC from TC (0–1 mitotic figures in 10 high-power
microscopic fields (HPF) for TC, 1–10 mitotic figures/10
HPF for AC, and >10/10 mitotic figures/10 HPF for
LCNEC).
Despite diagnostic criteria, inter-observer variability
exists between typical and atypical carcinoid tumors [3,4].
Furthermore, diagnostic challenges can occur in a biopsy
due to limited sampling or poor specimen handling (crush
artifact) [5]. A distinction is important because of the
different prognosis and treatment of carcinoid tumors
vs. high-grade neuroendocrine carcinomas [6,7]. SeveralThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and a poorer prognosis [8-14]. Ki-67 has been shown to
be more reliable and reproducible in distinguishing TC
from AC than histology [3]. Additionally, a very high
Ki-67 index can help distinguish LCNEC from AC when
classification is doubt.
While previous investigations have correlated clinico-
pathologic characteristics and Ki-67 index in carcinoid
tumors, relatively few studies have studied the spectrum
of TC, AC, and LCNEC and provided diagnostic nu-
meric criteria using Ki-67 similar to mitotic index. The
purpose of this study is to correlate Ki-67 mitotic index
calculated by digital image analysis with clinicopatho-
logic variables of non-small cell neuroendocrine tumors




A search of electronic pathology database with the key
words “carcinoid”, “large cell neuroendocrine”, and “neu-
roendocrine” of surgically resected lung tumors (wedge re-
section, lobectomy, pneumonectomy, airway resection)
from January 2003 to December 2014, inclusive, revealed
a total of 62 cases originally diagnosed as primary non-
small cell neuroendocrine tumors. The study only in-
cluded resection specimens; no biopsies were included.
Secondary, recurrent, and metastatic tumors were also ex-
cluded. One tumor originally diagnosed as “poorly differ-
entiated adenocarcinoma with neuroendocrine features”
was reclassified as large cell neuroendocrine tumor based
on the most recent World Health Organization criteria.
One tumor originally diagnosed as “high grade neuroen-
docrine tumor” was reclassified as small cell carcinoma
and excluded. Six tumors were excluded because of lack of
histological material.
Pathology and histological classification
All cases were reviewed by at least 2 study pathologists
to confirm their classification (ABP, SZL) based on the
current WHO criteria for lung neuroendocrine tumors.
TC was defined as well-differentiated neuroendocrine
tumor with 0–1 mitoses/10 HPF, and without necrosis.
ACs were distinguished by 2–10 mitoses/10 HPF and/or
focal necrosis. LCNECs had > 10 mitotic figures in 10
HPF, usually with large areas of necrosis; showed neuro-
endocrine morphology (nuclear palisading with nests,
rosette-like, or ribbons of cells); had prominent nucleoli
and cytoplasm unlike small cell carcinoma; and showed
immunohistochemical evidence of neuroendocrine dif-
ferentiation (diffuse staining for either synaptophysin,
chromogranin, or CD56 [15]. All tumors stained positive
for at least one of three neuroendocrine markers: synap-
tophysin, chromogranin, or CD56.The tumor size was obtained from the gross descrip-
tion in the surgical pathology laboratory. The tumor
location was obtained from clinical and radiological infor-
mation. Immunohistochemical staining was performed
using an automated immunostainer (BenchMark, Ventana,
Tucson, AZ) and Ultraview universal indirect biotin-free
DAB detection kit. The following neuroendocrine and pro-
liferative immunohistochemical markers were used: mouse
monoclonal synaptophysin (Ventana), mouse monoclonal
chromogranin-A (Ventana), mouse monoclonal CD56
(Ventana), and rabbit monoclonal Ki-67 (clone 30–9,
Ventana).
Mitotic count and Ki-67 proliferative index
The mitotic activity was manually quantitated in the
most cellular areas on whole-slide images scanned using
the Aperio imaging system (Leica Biosystems, Buffalo
Grove, IL); four 40x high power fields were calibrated as
1 mm2. The mitotic count was performed according to
the method recommended in the 7th edition of the AJCC
Cancer Staging Manual: enumerate mitoses in the most
mitotically active area (“hot spot”) and then extend mi-
totic count to adjacent contiguous fields. If no mitotic
activity is evident, random representative tumor fields
are scanned for mitoses.
The Ki-67 proliferative index (PI) was performed
blinded to any knowledge of mitotic counts and was
quantitated using a validated nuclear algorithm (Aperio,
Leica Biosystems, Buffalo Grove, IL), where slides were
scanned at 20× magnification using the Aperio Scan-
scope Console and the images were analyzed using Ima-
geScope Nuclear v9 algorithm software that reports the
total number of nuclei counted and the percentage of
positive cell nuclei. The Ki-67 digital image analysis had
been previously validated for clinical and research use
by comparing Aperio-generated results with scores using
the Chromovision ACIS system (which had, in turn, been
previously validated against manual Ki-67 counts) per-
formed on the same slides of breast cancers. In brief,
digital image analysis was completed twice for each test
case using the Aperio Imagescope algorithm, and the out-
puts were then averaged and compared to the Chromo-
vision ACIS results, which yielded the recommended
acceptable level of agreement [16]. In our study, digital
image analysis was executed by manually annotating at
least three representative non-necrotic tumor fields which
together contained at least total 2000 cells (or all tumor
cells if less than 2000) in which automated analysis was to
be performed. Positive staining was defined as faint nu-
clear positivity or greater (1+). Care was taken to exclude
fields containing substantial numbers of non-tumor cells,
such as endothelial cells and intratumoral lymphocytes,
and non-tumor cells were further excluded by calibrating
the algorithm thresholds for nuclear size (>10 um),
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to omit non-neoplastic cells. Limitation of scoring to
tumor cells was verified through visual review of the
marked-up digital images and the corresponding H&E-
stained scanned slide.
Statistical analysis
All statistical analyses were performed using JMP 10.0
statistical software (SAS, USA). ANOVA analysis was per-
formed between histological group (TC, AC, and LCNEC)
and Ki-67 index. Fisher’s two-sided exact test was used to
analyze categorical data (race, smoking, gender, necrosis).
Overall survival was calculated from the date of patho-
logical diagnosis to time of death or last follow-up, and
disease free survival was calculated from date of patho-
logical diagnosis to time of last clinical evidence of recur-
rence, progression, or death. Overall survival curves and
significance of survival and disease free survival distribu-
tions were generated using Kaplan-Meier and Log-RankTable 1 Pathological characteristics
All tumors
Mitotic count (#/10 HPF)‡ 10.4 ± 1.5
Range 0-79




















Large cell neuroendocrine 4
Small cell carcinoma 2
Poorly differentiated NSCLC 1
‡p < 0.0001, ANOVA, across all groups.
#p < 0.0001, Fisher's exact test, comparing large cell NE vs. typical carcinoid.
#p = 0.0192, Fisher's exact test, comparing large cell NE vs. atypical carcinoid.
#p < 0.0001, Fisher's exact test, comparing atypical carcinoid vs. typical carcinoid.method. All p-values were two-sided. Multivariate survival
fit was calculated by the Weibull parametric test.
Results
Patient population
There were a total of 55 lung neuroendocrine tumors:
39 TC, 7 AC, and 9 LCNEC. In three patients, the
neuroendocrine tumor was found incidentally: one TC
discovered at wedge resection for presumed metastatic
hepatocellular carcinoma, one TC discovered at pulmon-
ary explant for emphysema, and one synchronous TC
discovered at lobectomy for lung adenocarcinoma. There
were a total of 41 females and 14 males (3:1 ratio),
Clinical features
Clinical characteristics are summarized in Table 1. All
patients with LCNEC were smokers compared to 18 of 37
patients with TC or AC (49%)(p = 0.0050, Fisher’s exact
test, two-sided). There was a strong association withTypical Atypical Large cell
0.1 ± 0.2 3.4 ± 2.1 56.1 ± 17.0
0-1 2-8 25-73
2.3 ± 1.8 16.8 ± 7.7 81.3 ± 9.9
0 - 6.7 9.9 - 25.7 63.2 - 91.9
39 (0%) 4 (57%) 0 (0%)
0 (100%) 3 (43%) 9 (100%)
33 (85%) 5 (71%) 5 (56%)
6 (15%) 2 (29%) 4 (44%)
36 (92%) 7 (100%) 5 (56%)
3 (8%) 0 (0%) 4 (44%)
32 (82%) 5 (71%) 9 (100%)
7 (18%) 2 (29%) 0 (0%)
34 (87%) 6 (86%) 9 (100%)






Table 2 Clinical characteristics
All tumors TC AC LCNEC
n 55 39 7 9
Mean age±SD (yrs) 60.8 ± 11.2 61.8 ± 12.6 61.5 ± 6.5 55.2 ± 5.5
Range (yrs) 33.6-79.4 33.6-79.4 51.1-73.4 47.5-61.6
Sex
Females 41 (75%) 31 (80%) 5 (71%) 5 (56%)
Males 14 (25%) 8 (20%) 2 (29%) 4 (44%)
Race‡
White 41 32 6 3
Black 12 5 1 6
Other 2 2 0 0
Smoking hx†
Smoker 27 (59%) 16 (50%) 2 (40%) 9 (100%)
Nonsmoker 19 (41%) 16 (50%) 3 (60%) 0 (0%)
Data unavailable 9 7 2 0
Location
Central 46 (84%) 34 (87%) 6 (86%) 6 (67%)
Peripheral 9 (18%) 5 (13%) 1 (14%) 3 (33%)
Mean tumor
size ± SD (cm)
2.2 ± 1.5 2.1 ± 1.5 2.7 ± 1.9 2.8 ± 1.2
Range (cm) 0.2-6.9 0.2-6.9 0.7-5.5 0.4-4.5
Tumor stage (T)
T1a 26 19 3 4
T1b 10 8 2 0
T2a 16 10 1 5
T2b 1 1 0 0
T3 2 1 1 0
Nodal stage (N)
Nx 1 0 0 1
N0 46 35 5 6
N1 5 3 1 1
N2 3 1 1 1
Metastatic stage (M)
M0 53 39 6 8
M1 2 0 1 1
Procedure
Other 2 1 1 0
Wedge 14 5 2 7
Segmentectomy 2 2 0 0
Lobectomy 30 25 4 1
Bilobectomy 4 4 0 0
Pneumonectomy 3 2 0 1
AC = atypical carcinoid; TC = typical carcinoid; LCNEC = large cell
neuroendocrine carcinoma.
‡p = 0.0005 Fisher's exact test, LCNEC vs. TC and AC, Whites vs. Blacks.
†p = .005, LCNEC vs. AC and TC.
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0.0005, Fisher’s exact test, two-sided). Fifty-three tumors
were M0 and 2 tumors (one LCNEC, one AC) were M1 at
time of presentation. There was no association between
tumor size, location, TNM stage, gender, and age with
tumor histology.
Histological features
The histological characteristics are summarized in Table 2.
The ranges for mitotic count did not overlap by definition
(Figures 1, 2 and 3). In addition the Ki-67 index for TC,
AC, and LCNEC did not overlap (Figure 4). The mean mi-
totic count and Ki-67 index across all groups were statisti-
cally different (ANOVA, p < 0.0001). Among all tumors, in
aggregate, there was a strong correlation between mitotic
count and Ki-67 PI by linear regression (R2 = 0.90, p <
0.0001) (Figure 5). Necrosis, as expected, showed an in-
crease in incidence with higher grade (Table 2). There was
no significant difference in lymphovascular and perineural
invasion with increasing tumor grade (Table 2). Spindled
histology and osseous metaplasia were observed only in
TC and AC.
Survival and progression free survival analysis
Survival and progression free survival analysis are
summarized in Table 3. Available clinical information for
disease status at last follow-up was available in 47 of 55
cases, 33 of 39 TC, 7 of 7 AC, and 8 of 9 LCNEC. At the
end of the study, 11 patients were deceased: 3 with TC,
1 with AC, and 7 with LCNEC. Three patients with TC
died of other causes, two of which were known: one
from metastatic hepatocellular carcinoma and one from
recurrent pulmonary adenocarcinoma. There was no
disease recurrence in TC (0/33). Two patients with AC
had progression of disease: one with metastatic nodal
disease and one with distant metastases. The deceased
patient with AC had metastatic disease at initial presen-
tation, and died from disease 2.5 months after diagnosis.
Seven patients with LCNEC died of disease, one patient
is alive with recurrent disease,, and one patient did not
have sufficient follow-up. No survival difference was
observed between TC and AC. (Figure 6A). There was a
step-wise decrease in disease free survival with increas-
ing tumor grade: TC-not reached, AC- 35.5 months,
LCNEC- 10.1 months (Figure 6B). TC also had a signifi-
cantly improved disease free survival compared to AC
(p = 0.0168). There was also step-wise decrease in me-
dian overall survival with tumor grade. The median
overall survival was not reached in TC and AC and both
groups had significantly improved survival compared to
LCNEC (median OS- 18.3 months, p < 0.001).
Multivariate survival analysis was performed with
independent variables of age, gender, mitotic figures, and
Ki-67 index, with both recurrence and death as end-
Figure 1 Typical carcinoid. A. Typical carcinoid tumor with
osseous metaplasia showing anastomosing nests and cords. No
mitoses or necrosis are identified. B. Ki-67, 20x magnification,
showing 4.6% tumor positivity by digital image analysis.
Figure 2 Atypical carcinoid. A. H&E, 20x magnification, atypical
carcinoid showing a solid nested growth pattern and geographic
necrosis. Mitosis is not present in this field. B. Ki-67, 20x magnification,
showing 12.7% tumor positivity by digital image analysis.
Figure 3 Large cell neuroendocrine carcinoma. A.H&E, 20x
magnification, large cell neuroendocrine tumor with solid and
pseudoglandular growth patterns. Prominent nucleoli, geographic
necrosis, and mitoses are readily evident. B. Ki-67, 20x magnification,
showing 91.9% tumor positivity by digital image analysis.
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associated with death (p = .005) and recurrence (p = .02).
In contrast, mitotic rate was not significantly associated
with death (p = .07) or recurrence (p = 0.4), nor was age
(0.7 for both). Gender showed no significant association
with survival or recurrence (p > 0.05).Discussion
There is consensus that small cell carcinomas of the
lung, in addition to having a high mitotic rate, have a
Ki-67 PI greater than 50% [17-20]. However, there are
fewer data on Ki-67 PI regarding pulmonary TC, AC
and LCNEC. Most reported studies have used manual
methodologies for calculating Ki-67 PI. In these studies,
the mean Ki-67 PI for TC, AC, and LCNEC were 0.5-
3.7%, 2.4-20%, and 25-81% respectively [11,12,19,21-24].
There is no consensus threshold separating pulmonary
AC from TC and LCNEC, with reported cutoff threshold
ranging between 2.5% to 5% for TC v. AC, and a value
of 30% for AC v. LCNEC [9,11,12,19]. In the gastrointes-
tinal tract, corresponding cutoffs are 3% and 20%, using
both manual and automated Ki-67 methodology [25];
Yamaguchi, 2013 #41}, separating low from intermediate
grade, and intermediate grade from high-grade neuroen-
docrine carcinomas, respectively.
Figure 4 Ki-67 proliferative index by tumor type. Scatterplot of Ki67 index by histological type. Error bars represent standard deviation with
mean. TC = typical carcinoid; AC = atypical carcinoid; LCNEC = large cell neuroendocrine carcinoma.
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utilizing an established commercially available platform
(Aperio®) to quantify the Ki-67 PI of TC, AC, and
LCNEC. Our reported mean Ki-67 PI for TC, AC, and
LCNEC were 2.3%, 16.8%, and 81.3% respectively. A cut-
off of 7% reliably separated all TC and AC and a cutoff
of 50% was a reliable cutoff between AC and LCNEC,
with a wide interval of Ki-67 PI in which AC and
LCNEC did not overlap (30-60%). A similar study on cy-
tology smears, found a large range of Ki-67 PI (25-50%)
where low-grade neuroendocrine and high-grade neuro-
endocrine tumors did not overlap [17]. Our mean Ki-67Figure 5 Ki-67 proliferative index versus mitoses. Scatterplot with simp
Diamond-AC, Triangle- LCNEC. KI-67 PI (%) = 4.59 + 1.30 (mitoses/# 10HPF),proliferative index across the spectrum of neuroendocrine
tumors is somewhat higher than in most reported studies,
possibly due to our differences in methodology in our
using automatic cell counting – while this method has
been previously validated against manual counting in
breast cancers, it may have a lower threshold for counting
weakly positive cells than some observers. Indeed, one of
the strengths of automated quantitation of Ki-67 PI is
elimination of interobserver variability in threshold for
positivity. Our data for mean Ki-67 is similar to a recent
study by Watts et al., who reported a mean of 3.7% and
18.8% for TC and AC respectively [14]. However, a Ki-67le linear regression of KI-67 PI vs. mitosis (#/10 HPF). Dot- TC,
R2 = 0.89, p < 0.001.
Table 3 Reoccurrence and survival data
All tumors TC AC LCNEC
Clinical status at last f/u
Alive without recurrence 35 30 5 0
Alive with recurrence 2 0 1 1
Alive, unknown 7 6 0 1
Died with disease 8 0 1 7
Died of other causes 2 2 0 0
Died, unknown cause 1 1 0 0
Median disease free survival (months)† NR NR 35.5 10.1
Hazard ratio <0.01 0.10 1.00
Confidence interval (95%) - 0.01-0.57 -
P-value - <0.0001 0.0063 -
Mean DFS follow-up (months) 20.2 21.9 21.9 12.0
Median survival (months) NR NR NR 19.7
Hazard ratio 0.06 0.08 1.00
Confidence interval (95%) 0.01-0.24 0.00-0.54 -
P-value - <0.0001 0.0070 -
Mean OS follow-up (months) 29.6 31.4 34.3 18.3
†p = 0.0168, DFS, TC vs. AC.
AC = atypical carcinoid; TC = typical carcinoid; LCNEC = large cell neuroendocrine carcinoma.
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one LCNEC have been reported [14,24,26]. In an older
study by Costes et al., a Ki-67 of 0–3.0% for TC and
0–6.1% for AC was reported [9].
Determination of Ki-67 PI may be useful in small biop-
sies or in cytological specimens where diagnostic tissue is
limited for morphologic and proliferative activity assess-
ment due to small sample size and or crush artifact. In
these samples, a carcinoid tumor maybe over-diagnosed as
high-grade neuroendocrine tumor or vice versa [18,20].
Although this study was limited to resection specimens,
and the proposed cutoffs require validation before use in
small biopsy or cell block specimens, previous studies
seem to support the value of Ki-67 PI in such specimens.
Watanabe et al. found no mitotic figures in 7 of 38 small
biopsies of LCNECs, and 11 of 38 small biopsies had inad-
equate tumor volume for mitotic count (<10 HPF); never-
theless, a Ki-67 index could adequately be assessed in all
biopsies, and it was found to be in a range of 42-99% [24].
Furthermore, at least one study has shown Ki-67 PI is a
reliable test in inter-observer agreement between TC and
AC [3]. Accurate distinction between a high grade and
low to intermediate grade neuroendocrine tumor is im-
portant because of different biological behaviors, including
overall survival and disease free survival, among TC, AC,
and high-grade neuroendocrine tumors [7,15,21].
Digital image analysis of Ki-67 PI has been shown to
have improved diagnostic accuracy compared to visual es-
timation for neuroendocrine tumors of the gastrointestinaltract [27]. Tang et al. found that visual estimation is subject
to both low intra-observer and inter-observer agreement
for grading of gastrointestinal neuroendocrine tumors.
Compared to manual counting (of all individual tumor
cells), automated counting showed excellent concordance
(98%) [27]. The usefulness of automated Ki-67 in predict-
ing gastrointestinal neuroendocrine tumor has been clinic-
ally validated at least in one study [28].
The potential technical limitations of automated analysis
of Ki-67 PI are: a requirement for in-house validation of
the method against manual cell count; counting a suffi-
cient number of tumor cells to avoid misrepresentation of
Ki-67 from intra-tumoral variability; and methods to ex-
clude counting on non-tumor mitotic activity. Regarding
validation, the College of American Pathologists has
issued guidance on validation of quantitative assays for
estrogen receptor and progesterone receptor that are
helpful in establishing standards for clinical validation
[16]. Regarding cell counts, the WHO recommends
counting at least 500 cells for grading neuroendocrine
tumors of the GI tract; however, we tried to limit intra-
tumoral variability by using a much higher threshold of
2000 tumor cells across at least 3 distinct manually an-
notated representative tumor fields. Automated image
analysis renders scoring a large number of cells a trivial
additional burden. The last issue, exclusion of non-tumor
cells is the most complicated. The combination of manual
selection of tumor fields with few non-tumor cells, and
use of a counting system that uses size and/or other
Figure 6 Overall and disease free survival by tumor type. A: Kaplan-Meier Curves, overall survival by histological type. Although there is a
marked difference between LCNEC and carcinoid, there is no difference between typical and atypical carcinoid. B: Kaplan-Meier Curves, disease
free survival by histological type. The recurrence rate for AC is intermediate between TC and LCNEC.
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necessary to overcome this problem.
The current study reports similar results to previously
published data on overall survival between LCNEC and
carcinoid tumors. However, we did not find a difference
in overall survival between TC and AC, probably due to
relatively low number of AC (n = 7), a limitation in our
study. One patient with AC in our study was unusual, in
that death occurred 2.5 months after diagnosis, but this
patient had delayed medical treatment and was initially
diagnosed with distant metastasis. Our follow-up data
did show a marked biologic difference between LCNEC
and carcinoid tumors; all LCNEC with available follow-
up data (8/8) recurred with a poor median overall sur-
vival of 19.7 months. There was a significant stepwise
decrease in DFS with tumor grade, similar to previous
studies; the reported 5 year survival rates are 87-97%, 56-
78%, and 15%-40%, respectively for TC, AC, and LCNEC
[6-8,12,21,29,30]. We found a strong association between
black race, smoking and LCNEC, and in the latter, a trad-
itional risk factor shared with small cell carcinoma [6,7].
In contrast to other series showing no gender predilection[1], we showed a predominance of women (3:1 ratio) for
AC and TC.Conclusion
The current study identified cutoffs that reliably separated
surgically resected endocrine tumors of the lung by Ki-67
proliferative indexing using automated digital image ana-
lysis. With our system, which has been validated for prog-
nostication in breast cancers, a cutoff of 7% separated AC
from TC, and there was a wide area (between 30 and 60%)
that separated LNEC from AC.Competing interests
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